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Although loss-of-function mutations in the PARK2 gene, the gene that encodes the protein
parkin, cause autosomal recessive juvenile parkinsonism, the responsible molecular
mechanisms remain unclear. Evidence suggests that a loss of parkin dysregulates excitatory
synapses. Here we show that parkin interacts with the kainate receptor (KAR) GluK2 subunit
and regulates KAR function. Loss of parkin function in primary cultured neurons causes GluK2
protein to accumulate in the plasma membrane, potentiates KAR currents and increases
KAR-dependent excitotoxicity. Expression in the mouse brain of a parkin mutant causing
autosomal recessive juvenile parkinsonism results in GluK2 protein accumulation and
excitotoxicity. These ﬁndings show that parkin regulates KAR function in vitro and in vivo, and
suggest that KAR upregulation may have a pathogenetic role in parkin-related autosomal
recessive juvenile parkinsonism.
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A
lthough loss-of-function mutations in the PARK2 gene
cause the most common form of autosomal recessive
juvenile parkinsonism (ARJP)1,2, the underlying
molecular mechanism remains unclear. The PARK2 gene
encodes the parkin protein, an ubiquitin E3 ligase widely
expressed throughout the central nervous system whose
functions include targeting proteins for degradation3 and
modulating mitochondria turnover4,5. Beside these well-
recognized functions, increasing evidence suggests that parkin
also regulates excitatory synapses. Immunoﬂuorescence studies
have detected widespread parkin expression in neurons, including
dendrites and spines6. The carboxy-terminal domain of parkin
contains a class II PDZ-binding motif that binds the protein
CASK in postsynaptic densities7. Parkin associates with and
ubiquitinates the PDZ protein PICK1, thus modulating the
activity of ion channels involved in synaptic plasticity8. Parkin
also mediates endophilin-A1 ubiquitination and some evidence
suggests that endophilin-A-mediated parkin recruitment
promotes synaptic protein ubiquitination9. The loss of
endogenous parkin sensitizes in vitro midbrain dopaminergic
neurons to kainate toxicity10, increases excitatory glutamatergic
synapse numbers and increases vulnerability to synaptic
excitotoxicity in cultured hippocampal neurons6. Hence,
although current knowledge strongly suggests that parkin
intervenes in modulating glutamatergic synapse function, the
underlying molecular mechanism is unknown. We hypothesized
that parkin may directly regulate ionotropic glutamate receptors
of the N-methyl-D-aspartate (NMDAR), a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPAR) or kainate receptor
(KAR) types. Our results show that parkin regulates KAR
function and suggest that KAR may have a pathogenetic role in
parkin-related ARJP.
Results
Increased GluK2 levels in PARK2 brain tissues. The parkin-
Q311X transgenic model expresses a human parkin variant
causing ARJP11, and it is the ﬁrst parkin-based mouse model that
exhibits a neurodegenerative phenotype in vivo12. To test the
hypothesis that parkin regulates glutamate ionotropic receptors,
we analysed NMDAR, AMPAR and KAR subunit levels in
substantia nigra from parkin-Q311X mice and littermate age-
matched controls (mouse genotyping is reported in
Supplementary Fig. 1a). The levels of the KAR GluK2 subunit
were signiﬁcantly higher in lysates from parkin-Q311X mice than
from control mice (mean GluK2 values: controls 1.00±0.09
versus PARK2 1.51±0.08, unpaired t-test **P¼ 0.0010), whereas
the levels of AMPAR (GluA1 and GluA2/3) and NMDAR
subunits (GluN1 and GluN2B) were similar in the two groups
(Fig. 1a; GluK2a antibody validation is reported in Supplementary
Fig. 1b; full blotting images are reported in Supplementary Fig. 2).
To investigate whether GluK2 protein accumulates in ARJP
patients’ brains, we analysed NMDAR, AMPAR and KAR
subunit levels in brain lysates from healthy controls (n¼ 5) and
patients with the PARK2 mutation (n¼ 4). Patient’s data are
reported in Supplementary Table. 1. GluA1 subunit levels were
lower in brain lysates from patients than in those from controls
(mean GluA1 values: controls 1.00±0.01 versus PARK2
0.58±0.06, unpaired t-test ***P¼ 0.0001; Fig. 1b). GluK2
subunit levels were markedly higher in brain lysates from
patients than in those from controls (mean GluK2 values:
controls 1.00±0.03 versus PARK2 2.41±0.22, unpaired t-test
***P¼ 0.0002; Fig. 1b; full blotting images are reported in
Supplementary Fig. 3). GluK2 protein levels therefore increased
in two independent PARK2 models, the difference suggesting that
parkin may interact with and regulate GluK2 protein.
Parkin interacts with the KAR GluK2 subunit. We tested the
interaction hypothesis in HEK293T cells transfected with GluK2a
and parkin. We found that parkin co-immunoprecipitated with
GluK2a and that GluK2a co-immunoprecipitated with parkin
(Fig. 2a and Supplementary Fig. 4). The co-immunoprecipitation
intensities were weak but consistently above background levels.
Fluorescence resonance energy transfer (FRET) experiments
between GluK2a-YFP and CFP-parkin expressed in HEK293T
cells indicated a direct interaction between the two proteins
(Supplementary Fig. 5a). We therefore hypothesized that the
parkin-GluK2 interaction might be a transient phenomenon
dependent on agonist stimulation. We found that activation of
GluK2 KARs with 10mM glutamate increased parkin-GluK2a
interaction in HEK293T cells as assessed by immunoprecipitation
(untreated 1.00±0.27 versus glutamate treated 2.70±0.31,
unpaired t-test **P¼ 0.0061; Supplementary Fig. 5b) and FRET
experiments (Supplementary Fig. 5a).
We next investigated whether the parkin–GluK2 interaction
exists in brain tissues, and found that endogenous GluK2
co-immunoprecipitated with parkin in lysates from wild-type
(wt) mouse brains (Fig. 2b and Supplementary Fig. 6). No
co-immunoprecipitation was detected in the negative controls,
that is, lysates from parkin / and GluK2 / mouse brains
(Supplementary Fig. 5c). Finally, we showed that GluK2
co-immunoprecipitated with parkin in lysates from whole human
brains (Fig. 2b and Supplementary Fig. 6). The co-immunopre-
cipitation intensities were weak but consistently above back-
ground levels. Hence, these data show that parkin interacts with
GluK2.
Many GluK2 interactors bind to the GluK2 C-terminal
cytoplasmic tail, which corresponds to amino acids (aa)
841–908 in the human GluK2a isoform13. We therefore
conducted co-immunoprecipitation experiments between parkin
and GluK2a mutants with truncations of the C-terminal
tail. Parkin co-immunoprecipitated with all GluK2a mutants,
including the shorter GluK2a-850stop (Fig. 2c and
Supplementary Fig. 6), thus suggesting that parkin binds to aa
841–850 of GluK2a. A pull-down assay using biotinylated
peptides spanning the GluK2a C terminus and lysates from
human brain or HEK293T cells expressing FLAG-parkin showed
that parkin binds to GluK2a aa 841–850 and that parkin can also
bind to a second GluK2a domain lying between aa 873 and 877
(Fig. 2d and Supplementary Fig. 7). Once we had identiﬁed the
GluK2a domain responsible for parkin binding, we investigated
which parkin domain mediated parkin binding to GluK2. A pull-
down assay using GluK2a peptides and parkin domains showed
that parkin binding speciﬁcally depends on the Ubl-linker
domain (Fig. 2e and Supplementary Fig. 7). Hence, data from
Fig. 2 and Supplementary Figs 4–7 show that parkin interacts
directly with GluK2 and that the interaction is mediated by the
Ubl-linker domain of parkin and the proximal part of the GluK2
C-terminal cytoplasmic tail. In addition, glutamate stimulation of
KARs favours the parkin–GluK2 interaction.
Parkin can ubiquitinate GluK2. As parkin binding to GluK2
speciﬁcally depends on the Ubl-linker domain, which binds ubi-
quitination substrates14, we hypothesized that parkin could
ubiquitinate GluK2. To test this possibility, we incubated
puriﬁed GluK2a with HA-ubiquitin, E1, E2 (UbcH7) in vitro.
We observed that recombinant parkin increased GluK2 ubi-
quitination (no parkin 1.00±0.08 versus wt parkin 1.43±0.14,
unpaired t-test *P¼ 0.0201; Fig. 3a and Supplementary Fig. 8). We
conﬁrmed that parkin-ubiquitinated GluK2a expressed in
HEK293T cells transfected with Myc-GluK2a, HA-ubiquitin and
parkin. Transfection of parkin signiﬁcantly increased Myc-GluK2a
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ubiquitination, whereas transfection of the catalytically null
mutant parkinC431S left GluK2a ubiquitination unchanged
(controls 1.00±0.12 versus wt parkin 1.79±0.19 and
parkinC431S 1.04±0.08, ANOVA *P¼ 0.0219; Fig. 3b and
Supplementary Fig. 8). To investigate whether parkin can
ubiquitinate endogenous GluK2, we analysed GluK2
ubiquitination in primary hippocampal neurons. We silenced
endogenous parkin in primary hippocampal neurons by lentiviral
infection of a GFP-shRNA-parkin construct (Supplementary
Fig. 9). In these experiments, we detected a ubiquitin smear in
GluK2 immunoprecipitated samples; rat parkin silencing
decreased GluK2 ubiquitination, whereas co-expression of
shRNA-resistant human parkin (parkinR) increased GluK2
ubiquitination (sh-scrambled 1.00±0.10 versus sh-parkin
0.51±0.03 versus sh-parkinþ parkinR 0.90±0.10; ANOVA
*P¼ 0.0169; Fig. 3c and Supplementary Fig. 10). Hence, parkin
ubiquitinates GluK2 in vitro, GluK2 expressed in heterologous cell
cultures and GluK2 containing KARs in cultured hippocampal
neurons. Knockdown of parkin function signiﬁcantly decreases
endogenous GluK2 ubiquitination.
Loss of parkin increases KAR currents and excitotoxicity.
Given that KAR surface levels are regulated by GluK2 conjugation
to small ubiquitin-like modiﬁer protein-1 (ref. 15), we hypo-
thesized that GluK2 ubiquitination by parkin could regulate KAR
surface levels. We silenced endogenous parkin in primary
hippocampal neurons by lentiviral infection with GFP-shRNA-
parkin construct (Supplementary Fig. 9). We found that parkin
silencing speciﬁcally caused accumulation of endogenous GluK2
in the plasma membrane, whereas parkinR co-expression led to
the opposite effect (sh-scrambled 1.000±0.017 versus sh-parkin
2.053±0.274 versus sh-parkinþ parkinR 0.991±0.0572,
102
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Figure 1 | Increased GluK2 levels in brain tissues from the PARK2 mouse model parkin-Q311X and from patients with PARK2 mutations. (a) Western
blottings of glutamate receptor subunits in substantia nigra lysates from controls (n¼ 7) and littermate parkin-Q311X mice (n¼ 6). All mice were 3 to 4
weeks old. Samples were run in parallel gels, each gel contained wt and parkin-Q311X samples. Western blottings were blotted and developed
contemporaneously. Results derive from three independent experiments. The densitometer analysis shows that GluK2 protein is signiﬁcantly increased in
parkin-Q311X mice as compared with littermate controls (unpaired t-test, **P¼0.0010, t¼4.424). No statistically signiﬁcant differences were found for
the other AMPA, NMDA and KAR subunits analysed (unpaired t-test, P40.05). No GluK1 and GluN1 expression was detectable. Error bars indicate±s.e.m.
(b) Western blottings for glutamate receptor subunits in frontal cortex brain lysates from control subjects (n¼ 5) and PARK2 patients (n¼4). No GluK1
expression was detectable. Results derive from three independent experiments. The densitometer analysis shows that GluK2 protein is signiﬁcantly
increased in brain tissues from patients with PARK2 mutations (unpaired t-test; ***P¼0.0002; t¼ 7.259) and that GluA1 decreases in brain tissues from
patients with PARK2 mutations (unpaired t-test; ***P¼0.0001; t¼ 7.826). Error bars indicate±s.e.m.
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ANOVA **P¼ 0.0053; Fig. 4a and Supplementary Fig. 11). In
addition, we co-transfected neurons with sh-parkin and Myc-
GluK2a, and conﬁrmed by immunoﬂuorescence that parkin
silencing increased surface Myc-GluK2a (sh-scrambled
1.00±0.14 versus sh-parkin 1.61±0.17; sh-parkinþ parkinR
0.93±0.14; ANOVA **P¼ 0.0066; Fig. 4b).
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Figure 2 | Parkin interacts with GluK2. (a) Representative western blottings of co-immunoprecipitations in HEK293T cells transfected with FLAG-parkin
and Myc-GluK2a. The data show that FLAG-parkin co-immunoprecipitates with Myc-GluK2a and that Myc-GluK2a co-immunoprecipitates with
FLAG-parkin. The image is representative of ﬁve independent experiments. (b) Representative western blottings of co-immunoprecipitations between
endogenous parkin and GluK2 in whole mouse brain lysates and whole human brain lysates. The data show that GluK2 co-immunoprecipitates with parkin.
The image is representative of three independent experiments. (c) Western blottings of co-immunoprecipitation experiments from HEK293T cells
transfected with FLAG-parkin and Myc-GluK2a mutants truncated at aa 896, 868 and 850. Our terminology for these truncation mutants indicates the
position at which a stop codon was introduced. All the mutants were able to bind parkin. The data show that the parkin-GluK2a interaction is unaffected
by the loss of the last 58 aa of the GluK2a tail. The image is representative of four independent experiments. (d) Pull-down assay using biotinylated
peptides spanning the GluK2a C terminus and lysates from human brain or HEK293T cells expressing FLAG-parkin. GluK2a peptides that bind parkin are
indicated in red. The image is representative of ﬁve independent experiments. (e) Pull-down assay using biotinylated GluK2a peptides and lysates
from HEK293T cells expressing FLAG-parkin or amino-terminally ﬂagged parkin domains (FLAG-Ubl-linker; FLAG-R1; FLAG-R2). GluK2a peptides pulled
down FLAG-Ubl-linker of parkin. The image is representative of ﬁve independent experiments.
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Loss of parkin function was reported to enhance glutamatergic
synapse efﬁcacy6. Here we tested a speciﬁc regulation of KAR
function by parkin. We recorded currents evoked by kainate
application in cultured hippocampal neurons. To isolate KAR-
mediated currents evoked by kainate, we used GYKI 53655
(10 mM), a non-competitive AMPAR antagonist that does not
affect KARs16. KAR-mediated currents evoked in hippocampal
neurons expressing sh-parkin had higher amplitude than those
evoked in neurons expressing sh-scrambled. Co-transfection
with parkinR decreased KAR-mediated currents (ratio between
current intensity on kainateþGYKI 53655/kainate alone:
sh-scrambled 0.4579±0.03769; sh-parkin 0.6790±0.03642;
HA-ubiquitin
Myc-GluK2
E1
E2
ATP
Parkin
225
IB: Myc
IP: GluK2
sh-scrambled
sh-parkin
ParkinR
HA-Ubi
150
102
225
150
102
76
52
IB: parkin
IB: GluK2
IB: HA
IP: IgG INPUT
–
–
–
–
–
+
+
+
+
+++
–
–
–
–
–
+
+
+
+
+++
–
–
–
–
–
+
+
+
+
+++
0.00
0.25
0.50
0.75
1.00
H
A-
ub
iq
ui
tin
/M
yc
-G
lu
K2
n
o
rm
a
liz
ed
 in
te
ns
ity
1.25
*
sh
-pa
rki
n
sh
-sc
ram
ble
d
sh
-pa
rki
n+
pa
rki
nR
0.0
0.5
1.0
1.5
H
A-
ub
iq
ui
tin
/M
yc
-G
lu
K2
n
o
rm
a
liz
ed
 in
te
ns
ity
2.0
*
No
 pa
rki
n
Pa
rki
n W
T
IB: HA
IB: parkin
52
76
102
150
225
+
+
+
+
+
+
+
+
+
+
+
+
–
–
+
+
+
+
150
Myc-GluK2
Parkin-wt
HA-Ubi
IP: Myc IP: IgG INPUT
+
+
+++
+
+
–
––
–
–
+ +
+
+
+ ++
–
––
–
++ +
+
+
+ ++
–
––
–
++ +
+
+
+ ++
–
––
–
+
+
+
+++
+
+
–
––
–
–
+
+
+++
+
+
–
––
–
–
225 IB:
Myc
IB:
HA
IB:
0.0
0.5
1.0
1.5
H
A-
ub
iq
ui
tin
/M
yc
-G
lu
K2
n
o
rm
a
liz
ed
 in
te
ns
ity
2.0 *
INPUTIP: IgGIP: Myc
Myc-GluK2
Parkin-wt
Parkin-C431S
HA-Ubi
225
150
225
150
102
76
parkin
IB:
IB:
HA
IB:
No
 pa
rki
n
Pa
rki
n W
T
Pa
rki
n C
43
1S
Myc
parkin
150
225
150
102
76
Figure 3 | Parkin ubiquitinates GluK2. (a) In vitro ubiquitination assay of Myc-GluK2a using recombinant E1 (human ubiquitin-activating enzyme E1),
recombinant E2 (UbcH7), HA-ubiquitin and parkin. Myc-GluK2a was slightly ubiquitinated in the presence of E1 and E2 alone but recombinant parkin
signiﬁcantly increased GluK2a ubiquitination. Results are representative of nine independent experiments (two-tailed unpaired t-test, *P¼0.0201,
t¼ 2.580, df¼ 16). Error bars indicate±s.e.m. (b) Western blotting of co-immunoprecipitation using HEK293T cells transfected with Myc-GluK2a,
HA-ubiquitin, wt parkin or parkin C431S. GluK2a was ubiquitinated in HEK293T cells and parkin transfection signiﬁcantly increased GluK2a ubiquitination.
Parkin C431S transfection did not increase GluK2a ubiquitination. Results are representative of three independent experiments (one-way analysis of
variance (ANOVA) and Tukey test, *P¼0.0219, F¼9.029). Error bars indicate±s.e.m. (c) Western blotting of co-immunoprecipitation using primary
hippocampal neurons transfected with HA-ubiquitin and infected with lentiviral particle encoding sh-parkin or sh-scrambled, or sh-parkinþ parkinR.
Endogenous parkin silencing signiﬁcantly decreased endogenous GluK2 ubiquitination. ParkinR overexpression rescued endogenous GluK2 ubiquitination.
The image is representative of three independent experiments that gave identical results (one-way ANOVA and Tukey test, *P¼0.0169, F¼8.689). Error
bars indicate±s.e.m.
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sh-parkinþ parkinR 0.3555±0.04194; ANOVA **Po0.01 sh-
scrambled versus sh-parkin; ANOVA ***Po0.001 sh-parkin
versus sh-parkinþ parkinR; Fig. 4c). These data show that loss of
parkin function increases the level of endogenous KARs, thus
resulting in increased KAR currents evoked by kainate.
We next tested whether the KAR currents increase resulting
from the loss of endogenous parkin increased neuron vulner-
ability to excitotoxicity. We measured cell death rates in primary
hippocampal neurons treated with moderate kainate concentra-
tions (2–4 mM) plus concanavalin A (200 mgml 1), a lectin that
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speciﬁcally blocks KAR desensitization. Kainate plus concanava-
lin A induced dose-dependent cell death selectively in sh-parkin
neurons (kainate 2mMþConcA 200 mgml 1: sh-scrambled
6.15±3.90 versus sh-parkin 15.80±3.12, ANOVA *Po0.05;
kainate 4 mM: sh-scrambled 2.40±1.29 versus sh-parkin
42.21±5.20, ANOVA ***Po0.001). Co-transfection with par-
kinR rescued neuronal cell death (kainate 2 mMþConcA
200mgml 1: sh-parkinþ parkinR 3.20±1.56; kainate 4mMþ
ConcA 200 mgml 1: sh-parkinþ parkinR 8.39±3.38). Co-treat-
ment with KAR antagonist NS102 (ref. 17) (20–150mM) rescued
cell death (value for sh-parkin: kainate 4 mMþConcA
200mgml 1, 36.20±6.07 versus untreated 2.56±1.73, ANOVA
###Po0.001; kainate 4 mMþConcA 200mgml 1þNS102
20 mM 7.46±4.44, ANOVA **Po0.01 versus kainate 4mMþ
ConcA200mgml 1; kainate 4 mMþConcA 200 mgml 1þ
NS102 50 mM 17.01±5.72, ANOVA *Po0.05 versus kainate
4 mMþConcA 200 mgml 1; kainate 4 mMþConcA
200mgml 1þNS102 100 mM 10.58±4.57, ANOVA **Po0.01
versus kainate 4 mMþConcA200 mgml 1; kainate 4 mMþ
ConcA 200mgml 1þNS102 150 mM 11.84±3.41 ANOVA
**Po0.01 versus kainate 4 mMþConcA200 mgml 1). Co-
treatment with the AMPAR antagonist GYKI53655 did not
rescue cell death (value for sh-parkin: kainate 4 mMþConcA
200mgml 1þGYKI53655 10 mM 37.05±3.80, ANOVA
P40.05 versus kainate 4 mMþConcA200 mgml 1; Fig. 4d).
Hence, these data show that loss of parkin function increases the
vulnerability of hippocampal neurons to KAR-dependent
excitotoxicity.
To test whether the increased GluK2 levels were associated
with increased vulnerability to excitotoxicity in vivo, we analysed
neuronal levels of cleaved spectrin (non-erythroid alpha II-
spectrin) and cleaved calcineurin A, both well-recognized
markers for excitotoxic damage18–20. Cleaved spectrin and
cleaved calcineurin A were signiﬁcantly higher in substantia
nigra of parkin-Q311X mice than in littermate controls
(cleaved spectrin: wt 1.00±0.22 versus parkin-Q311X
2.87±0.60, unpaired t-test **P¼ 0.0096; cleaved calcineurin A:
wt 1.00±0.05 versus parkin-Q311X 1.23±0.05, unpaired
t-test *P¼ 0.0124; Fig. 4e and Supplementary Fig. 12).
Hence, the increased GluK2 levels and excitotoxicity markers in
our experiments disclosed in substantia nigra of parkin-Q311X
mice suggest that KAR upregulation induces excitotoxicity
in vivo.
Discussion
In this study, we describe major new ﬁndings that extend our
current knowledge about the molecular mechanism through
which parkin regulates glutamatergic synapses6. Parkin interacts
with and ubiquitinates the GluK2 KAR subunit and regulates
GluK2 levels and KAR currents. A loss of parkin function
increases KAR-dependent excitotoxicity in vitro and mutant
parkin expression correlates with GluK2 accumulation and
excitotoxicity features in vivo. Besides showing that parkin
regulates KAR currents, we specify that it does so by binding to
the GluK2 C-terminal cytoplasmic tail. Parkin-GluK2 binding
appears as a transient effect dependent on KAR activation by
agonists. As parkin affects somatodendritic KAR currents, the
parkin-GluK2 interaction probably takes place at post-synaptic
sites. Given that parkin is also localized in axons21, we cannot
exclude the possibility that parkin regulates pre-synaptic GluK2-
containing KARs, which are involved in the facilitation of
synaptic transmission22. GluK2a interacts with Ubl-linker
domain of parkin, similar to other parkin substrates23. The
accumulation of GluK2 we found in brains from patients with
PARK2mutations and in the PARK2mouse model parkin-Q311X
further indicates that GluK2 is a ‘genuine’ parkin substrate. By
identifying GluK2 as a parkin substrate, our results add to the
evidence that parkin can ubiquitinate synaptic proteins8,24,25. As
parkin activation is a multistep process involving relocalization
and release of ubiquitination activity, which are probably
regulated through phosphorylation or cysteine modiﬁcation, or
ligand binding to the Ubl domain26,27, we can speculate that
GluK2 binding to Ubl domain may induce parkin activation.
The loss of parkin function increases surface and total GluK2
levels, and consistently increases KAR currents. These data agree
with previous ﬁndings demonstrating that a loss of endogenous
parkin increases excitatory synaptic transmission6. By identifying
KAR as a direct target of parkin, our results provide a step ahead
towards understanding the mechanism through which parkin
modulates synaptic functions.
Our molecular ﬁndings also provide new insights into the
mechanisms responsible for neurodegeneration in patients with
ARJP. Similar to sporadic Parkinson’s disease, ARJP typically
causes massive dopaminergic neuronal depletion in the sub-
stantia nigra pars compacta (SNc)28, a brain region receiving
glutamatergic inputs from cortex, pedunculopontine nuclei29,
superior colliculus30, thalamus31 and subthalamic nucleus (STN).
Figure 4 | Loss of parkin function increases surface GluK2 levels, KAR currents and causes excitotoxicity. (a) Surface biotinylation assay in
hippocampal neurons infected with lentivirus encoding sh-scrambled or sh-parkin, or sh-parkinþ parkinR. Endogenous parkin silencing increased surface
GluK2 levels; co-infection with lentivirus encoding parkinR rescued GluK2 surface levels (one-way analysis of variance (ANOVA)–Dunnett’s multiple
comparison test, **P¼0.0053, F¼ 14.25). (b) Surface Myc labelling in hippocampal neurons co-transfected with sh-parkinþMyc-GluK2a or
sh-scrambledþMyc-GluK2a, or sh-parkinþ parkinRþMyc-GluK2a (one-way ANOVA–Bonferroni test, **P¼0.0066, F¼ 6.082, 29 degrees of freedom;
ten neurons analysed/each condition). Scale bar, 20mm. (c) KAR current analysis in hippocampal neurons infected with lentivirus encoding GFP bicistronic
sh-scrambled or sh-parkin, or sh-parkinþ parkinR. Whole-cell responses were induced by rapid application of 100mM kainate. To isolate KAR currents
from those resulting from AMPAR opening, we added 10 mM GYKI 53655 (IC50¼0.9±0.08mM)16. Responses are shown before application (left panel),
during the concomitant application of GYKI53655 (central panel) and after GYKI53655 washout (right panel). Western blotting shows parkin expression in
the three experimental conditions. The chart plot shows the ratio between current stimulated by kainateþGYKI53655 and the current triggered
by 3 s application of kainate alone (one-way ANOVA and Tukey test, **Po0.01; ***Po0.001; F¼ 15.87). Error bars indicate 25th and 75th percentiles.
(d) Primary hippocampal neurons were infected with lentivirus encoding GFP bicistronic sh-scrambled or sh-parkin, or sh-parkinþ parkinR. Data represent
the percentage of infected cells (green ﬂuorescent cells) labelled by propidium iodide (PI). Kainate 2–4mM or concanavalin A 200mgml 1 alone did not
induce cell death. Kainate 2–4 mMþ concanavalin A 200mgml 1 caused excitotoxicity in parkin-silenced cells. Co-infection with lentivirus encoding
parkinR rescued cell death (one-way ANOVA–Tukey test, *Po0.05 versus sh-scrambled 2 mM kainate; ***Po0.001 versus sh-scrambled 4mM kainate;
F¼ 20.02). NS102 20–150mM blocked excitotoxicity in parkin-silenced neurons (one-way ANOVA–Dunnett’s multiple comparison test, *Po0.05,
**Po0.01, versus kainate treated; ###Po0.001 versus untreated, F¼ 7.268). GYKI53655 (10mM) did not rescue cell death. (e) Western blottings for
cleaved spectrin and cleaved calcineurin A in substantia nigra lysates from 3-week-old controls (n¼ 7) and littermate parkin-Q311X mice (n¼6). Results
derive from three independent experiments (unpaired t-test, **P¼0.0096, t¼ 3.128 for cleaved spectrin; *P¼0.0124, t¼ 2.941 for cleaved calcineurin A).
All error bars in Fig. 4 histograms indicate±s.e.m.
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These brain anatomical connections make the SNc neurons
highly vulnerable to glutamate and suggested the longstanding
hypothesis that SNc neuron depletion in Parkinson’s disease may
stem from excitotoxicity32,33. SNc neurons abundantly express
KAR subunits34. Although KAR function in the SNc remains
elusive, our ﬁndings, showing that a loss of parkin function
increases KAR function, support the excitotoxicity hypothesis in
parkin-related ARJP. Current knowledge shows that in
parkinsonian patients’ brain, the STN displays irregular burst
ﬁring deriving from dopamine deﬁciency32, resulting in high
release of glutamate in the SNc, thereby causing excitotoxic
damage33,35. In this context, a parkin loss of function may cause
primary excitotoxic damage that would transiently precede the
excitotoxic damage, depending on the overactivity in the STN
glutamatergic neurons.
Hence, our results, suggesting that parkin modulates excitatory
currents by binding to and promoting GluK2 ubiquitination,
support the hypothesis that a loss of neuronal parkin increases
vulnerability to excitotoxicity6 and suggest that patients with the
PARK2 mutation might beneﬁt from neuroprotective therapy
targeting KAR.
Methods
Glutamate receptor subunit analysis in mouse brain tissues. Parkin-Q311X
(A) mice and littermate controls (all mice were female FVB/N strain) were pur-
chased from Charles River (Calco, Italy). Mice were kept under environmentally
controlled conditions on a 12-h light/dark cycle with food and water ad libitum.
Three- to four-week-old mice were killed and the substantia nigra were immedi-
ately dissected out on ice. Tissues were homogenized with lysis buffer (20mM Tris,
pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, protease
inhibitors (Roche), 50mM MG132 and 10mM N-ethylmaleimide (Sigma)). Wes-
tern blottings were performed with Novex NuPAGE SDS–PAGE gels (Invitrogen).
The following antibodies were used: GluA1 (13185, Cell Signaling, 1:500), GluA2/3
(AB1506, Millipore, 1:1,000), GluN2B (PA5-18536, Thermo Scientiﬁc, 1:300),
GluK2 (TA310550, Origene,1:1,000) and GluK3 (H0002899, Abnova, 1:2,000),
GAPDH (sc-25778, Santa Cruz, 1:1,000), Calcineurin A (ADI-SPA-610, Enzo Life
Sciences 1:1,000) and Spectrin (2122, Cell Signaling, 1:1,000). The study was
approved by The Ethics Committees of IRCCS Istituto Auxologico Italiano
‘‘Comitato Etico dell’IRCCS Istituto Auxologico Italiano di Milano’’. Experimental
procedures took place in accordance with the European Communities Council
Directive (86/809/EEC).
Glutamate receptor subunit analysis in human brain tissues. Control and
PARK2 post-mortem brain tissues were from the Department of Neurology,
Juntendo University School of Medicine. The study protocol was approved by the
Human Ethics Review Committee at Juntendo University School of Medicine.
Informed consent to use human tissues were obtained from patients or close family
members. Patients’ data are reported in Supplementary Table 1. Control brain
tissues were autopsied brain tissue from age-matched controls who had undergone
neuropathological examination to exclude neurodegenerative disorders. Tissues
were homogenized with lysis buffer (20mM Tris, pH 7.5, 150mM NaCl, 1mM
EDTA, 1mM EGTA, 1% Triton X-100, protease inhibitors (Roche), 50 mM MG132
and 10mM N-ethylmaleimide (Sigma)). Western blottings were performed with
Novex NuPAGE SDS–PAGE gels (Invitrogen). The following antibodies were used:
GluA1 ((13185, Cell Signaling, 1:500), GluA2/3 (AB1506, Millipore, 1:1,000),
GluN1 (clone N308/48, NeuroMab, 1:300), GluN2B (PA5-18536, Thermo Scien-
tiﬁc, 1:300), GluK1 and GluK3 (H0002897 and H0002899, respectively, Abnova,
1:2,000), GluK2 (TA310550, Origene, 1:1,000), parkin (P6248, Sigma, 1:6,000),
GAPDH (sc-25778, Santa Cruz, 1:1,000).
Analysis of GluK2–parkin interaction. Plasmids encoding complementary DNA
for human parkin and parkin domains (Ubl-linker, aa 1–237; RING1, aa 217–310;
RING2, aa 395–465) were described previously36. Plasmids encoding truncated
GluK2 mutants were created by mutagenizing the Myc-GluK2a(R) plasmid37 using
the QuikChange mutagenesis kit (Stratagene). Samples were immunoprecipitated
as described38 according to the following protocol: 500mg of sample were pre-
cleared by adding 50ml of washed Protein A or G agarose bead slurry (catalogue
number 17-5138-01 and 17-0618-01, GE Healthcare). The agarose beads were
collected by pulsing 5 s in the microcentrifuge at 14,000 g and discarded. Sample
supernatants were incubated with Myc antibody (R950, Invitrogen, 1:500) or
parkin antibody (P6248, Sigma, 1:1,000), or FLAG antibody (M2, Sigma, 1:500) at
4 C overnight. Fifty microlitres of washed Protein A or G agarose bead slurry were
added to the reaction mixture and gently rocked at 4 C for additional 2 h. The
agarose beads were then collected by pulsing 5 s in the microcentrifuge at 14,000 g
and washed three times with ice-cold washing buffer (20mM Tris, pH 7.5, 500mM
NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, protease inhibitors (Roche),
50 mM MG132). The beads were resuspended in 40 ml of 2 Laemmli sample
buffer, boiled, analysed by SDS–PAGE with Novex NuPAGE SDS–PAGE gels
(Invitrogen).
For pull-down experiments, lysates (150 mg) were incubated overnight at 4 C
with 15mg of biotinylated peptide (Primm srl) previously conjugated to
streptavidin-conjugated magnetic beads (Invitrogen), washed in lysis buffer,
resuspended in SDS sample buffer and boiled. Gels were silver-stained with the
SilverQuest Silver Staining Kit (Invitrogen). Parkin was labelled by parkin antibody
(P6248, Sigma) or FLAG antibody (M2, Sigma).
FRET analysis. Parkin cDNA was subcloned into a pECFP-C1 vector (Clontech).
The plasmid encoding GluK2a C-terminally conjugated to enhanced yellow
ﬂuorescence protein (YFP) has been previously described39. FRET videos were
acquired with an AF6000 microscope (Leica) equipped with a FRET excitation and
emission fast ﬁlter wheel and a  100 oil objective at a rate of one frame per
minute. Each frame was acquired on three channels: CFP excitation and CFP
emission (CFP), CFP excitation and YFP emission (FRET), and YFP excitation and
YFP emission (YFP). FRET efﬁciency was calculated pixel-by-pixel according to the
following formula (1):
EAðiÞ ¼ BAbCgC
where A, is the ﬂuorescence intensity measured in the CFP channel, and B and C
are the ﬂuorescence intensities measured in the FRET and YFP channels, whereas b
and g are correction factors for the spectral bleed throughout our constructs (Leica
LAS AF software method 1). FRET efﬁciency increase was calculated by comparing
the FRET efﬁciency distribution for three frames before and after treating for
10min with 10mM glutamate.
Ubiquitination assays. For in vitro ubiquitination assay, puriﬁed Myc-tagged
GluK2 (1mM, Origene) was incubated in ubiquitinylation assay buffer (10
buffer, 5mM Mg-ATP, 1mM dithiothreitol and 20Uml 1 pyrophosphatase;
Biomol) together with 100 nM recombinant human ubiquitin-activating enzyme E1
(Biomol), 2.5 mM recombinant E2 UbcH7 (Biomol), 2.5 mM haemagglutinin (HA)-
tagged ubiquitin and 100 nM recombinant His-tagged parkin (Boston Biochem) for
2 h at 37 C. The samples were immunoprecipitated with Myc antibody (R950,
Invitrogen) and analysed by western blotting.
For ubiquitination assay in HEK293T, cells were transfected with plasmid
encoding human parkin wt, parkin C431S, MycGluK2a plasmid and HA-ubiquitin.
Cells lysates were immunoprecipitated with Myc antibody (R950, Invitrogen).
Immunoprecipitated samples were analysed by western blotting with horseradish
peroxidase-conjugated antibody against Myc (R951-25, Invitrogen) and HA
(130-091-972, Miltenyi Biotec).
For analysis of endogenous GluK2 ubiquitination in primary neurons, lysates
were immunoprecipitated with anti GluK2/3 antibody (clone NL9 Millipore)
according to the manufacturer’s protocol. Five hundred micrograms of sample
were pre-cleared by adding 50 ml of washed Protein A agarose bead slurry
(catalogue number 17-5138-01, GE Healthcare). The agarose beads were collected
by pulsing 5 s in the microcentrifuge at 14,000 g and discarded. Sample
supernatants were incubated with 7.5 ml of anti-GluK2/3 at 4 C overnight. Fifty
microlitres of washed Protein A agarose bead slurry were added to the reaction
mixture and gently rocked at 4 C for additional 2 h. The agarose beads were then
collected by pulsing 5 s in the microcentrifuge at 14,000 g and washed three times
with ice-cold washing buffer (20mM Tris, pH 7.5, 500mM NaCl, 1mM EDTA,
1mM EGTA, 1% Triton X-100, protease inhibitors (Roche), 50 mM MG132). The
beads were resuspended in 40 ml of 2 Laemmli sample buffer, boiled, analysed by
SDS–PAGE with Novex NuPAGE SDS–PAGE gels (Invitrogen) and developed
with an antibody against HA (H6908, Sigma, 1:1,000).
Lentiviral infections in neurons. Primary rat hippocampal neurons were prepared
from embryonic day 18–19 rat brains38 and plated on poly-D-lysine (30 mgml 1)-
coated coverslips at densities of 75,000 cells per well for immunochemistry, 300,000
cells per well for biochemistry experiments and 150,000 cells per well for
electrophysiological experiments. Neurons were infected with lentivirus at Days in
Vitro (DIV) 8 (ref. 40). The pRNAT plasmid encoding short hairpin RNA
(shRNA) speciﬁc against rat parkin and scrambled have been previously
described6: parkin shRNA sequence was 50-CCAAACCGGATGAGTGGAGAGT
GCCAATC-30 . The same shRNA sequences were subcloned into the pLVTHM
plasmid and used to prepare lentiviral particles. Rescue experiments were
performed by expression of human parkin cDNA.
Biotinylation assay and immunoﬂuorescence in neurons. Plasma membrane
proteins were biotinylated using membrane-impermeant sulfo-NHS-SS-biotin
(0.3mgml 1, Pierce) for 5min at 37 C. Labelled neurons were washed with TBS
supplemented with 0.1mM CaCl2, 1.0mM MgCl2 and 50mM glycine. After fur-
ther washes with TBS supplemented with 0.1mM CaCl2 and 1.0mM MgCl2 on ice,
the cells were lysed in extraction buffer (50mM Tris-HCl, pH 7.4, 1mM EDTA,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6182
8 NATURE COMMUNICATIONS | 5:5182 | DOI: 10.1038/ncomms6182 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
150mM NaCl, 1% SDS and protease inhibitor mixture). Lysates were boiled for
5min and immunoprecipitated with streptavidin-conjugated magnetic beads
(Dynabeads, Invitrogen).
For immunoﬂuorescence, neurons were transfected at DIV 13–14 with the
Myc-GluK2a(R) plasmid using the calcium phosphate method40. For surface
staining, live DIV 18 hippocampal neurons were incubated for 10min at 37 C with
Myc antibody. After washing (PBS supplemented with 1mM MgCl2 and 0.1mM
CaCl2), neurons were ﬁxed for 7min at room temperature in 4%
paraformaldehyde/4% sucrose without permeabilization and stained with a Cy3-
conjugated secondary antibody (Invitrogen) applied in gelatin detergent buffer
(30mM phosphate buffer at pH 7.4 containing 0.2% gelatin, 0.5% Triton X-100
and 0.8M NaCl). Fluorescent images were acquired and quantiﬁed40: labelled
transfected neurons were chosen randomly for quantiﬁcation from four coverslips
from ﬁve independent experiments for each construct. Fluorescence images were
acquired with a Biorad MRC1024 confocal microscope, using a Nikon  60
objective with sequential acquisition setting at 1,280 1,024 pixel resolution. All
morphometric measurements were made with Metamorph image analysis software
(Universal Imaging Corporation). Both image acquisition and morphometric
quantiﬁcation were performed by investigators who were ‘blind’ to the
experimental condition.
KAR current recording in in vitro neurons. Whole-cell patch-clamp data were
recorded from DIV 19–21 primary hippocampal neurons (clamped at  70mV).
The coverslips were perfused with the following extracellular solution (mM): 140
NaCl, 3 KCl, 2 CaCl2, 1.2 MgCl2, 10 glucose and 10 HEPES (pH 7.4). Borosilicate
glass pipettes (5–8MO resistance) were ﬁlled with the following solution (mM):
126 K-gluconate, 4 NaCl, 10 HEPES, 10 glucose, 1 MgSO4, 0.5 CaCl2, 1 EGTA, 3
ATP-Mg and 0.1 GTP-Na (pH 7.2). Recordings were accepted for analysis when
membrane resistance (Rm) was 4150MO, series resistance (Rs) was o15MO
and, together with membrane capacitance (Cm), they changed by no more than
10% from the original value during the recording. Holding currents were lower
than  100 pA and remained signiﬁcantly unchanged throughout the experiments
(Rm¼ 268±31MO, Rs¼ 9.1±0.6MO, Cm¼ 42.2±2.3 pF and holding current
 39.0±5.2 pA). Signals were derived using a Multiclamp 700B ampliﬁer (Axon
Instruments), digitized through a Digidata 1440A interface (Axon Instruments)
and acquired for online visualization and ofﬂine analysis using pClamp10 Software
(Axon Instruments). Data were recorded at 28–30 C using a TC-324B temperature
control (Warner Instruments).
Excitotoxicity assay. Neurons were infected at DIV 8 with green ﬂuorescent
protein (GFP) sh-scrambled or sh-parkin or sh-parkinþ parkinR. One week after
infection, neurons were treated as indicated in Fig. 4d. Eight hours after the
treatment, neurons were washed in standard neurobasal medium and then incu-
bated with 1 mgml 1 of propidium iodide for 10min. Coverslips were PBS washed,
ﬁxed with 4% paraformaldehyde for 10min and mounted with ProLong mounting
DAPI (40,6-diamidino-2-phenylindole) (Invitrogen, P36931). Images were acquired
at confocal microscopy (Nikon Eclipse C1) and neurons were counted in ten ﬁelds
from each coverslip. The percentage of dead neurons was calculated as the ratio
between red-labelled neurons (propidium iodide) and green ﬂuorescent cells (GFP
infected). Approximately 800 to 1,300 neurons were scored for each condition.
Experiments were repeated three times each on three separate cultures.
Statistical analysis. Statistical analyses were performed using GraphPad Prism4
software. Data were subjected to normality test (Kolmogorov–Smirnov test). Stu-
dent’s t-test was used to compare two groups and one-way analysis of variance
followed by appropriate post-hoc tests was used to compare multiple groups. Data
are presented as mean±s.e.m.
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